论文信息 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). - 字舞流文

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

M. Kudo | S. Kaneko | A. Zhu | R. Finn | M. Ikeda | T. Kubota | A. Baron | T. Okusaka | A. Siegel | M. Kobayashi | H. Kumada | M. Sung | K. Ishikawa | S. Kraljevic